Antibody responses declined but T cell responses remained 12 weeks after Sinopharm second dose – USJ research

The Sinopharm is an inactivated COVID-19 vaccine, which is currently given emergency use authorization by the WHO and is the main vaccine used in many Asian and Middle East Countries. A new study was carried out to determine the kinetics and persistence of immune responses following the Sinopharm/BBIBP-CorV, by investigating the immune responses in a cohort of Sri Lankan individuals.

“Antibody responses declined in all age groups, especially in those who are more than 60 years after 12 weeks from the second dose, while T cell responses persisted.” Said Prof. Neelika Malavige, Head, Department of Immunology and Molecular Medicine of University of Sri Jayewardenepura. 

USJ researchers including Prof. Neelika Malavige and Dr. Chandima Jeewandara from Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine of University of Sri Jayewardenepura have been studying immune responses to different types of COVID-19 vaccines used in Sri Lanka.

Results of the current research show  that  while  the  SARS-CoV-2 specific total antibodies, and especially neutralizing antibodies and antibodies to the receptor binding domain significantly declined, the memory T cell and B cell responses persisted.

“Since the ACE2 receptor blocking antibodies (neutralizing antibodies that associate with protection) was shown to significantly decline in all age groups and especially in  the  elderly, it  is  important  to  carry out long term efficacy studies to assess the waning of immunity on hospitalization and severe disease in order to decide on booster doses in different populations.” said Prof. Malavige.

Download the PDF file : Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals.

The highlighted results of the study are available here : Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals

 

 

Related Articles :

90 percent of the new cases in Colombo belonged to the Delta variant says Dr. Jeewandara

Over 95% individuals developed antibodies against the Sinopharm vaccine – USJ Researchers

Research on Immunological response to COVID-19 vaccines by the Department of Immunology and Molecular Medicine, USJ

Single dose of Sputnik V is highly effective but second dose is beneficial says USJ researchers

USJ researchers found Four mutant Covid Delta variants with two new Sri Lankan mutations (A701S, R24C)

Delta variant was responsible for 95.8% of Covid-19 infections in Sri Lanka – Allergy, Immunology Cell Biology Unit, USJ

Whole genomic sequencing of the SARS-CoV-2 variants in Sri Lanka issued by Dept. of Immunology and Molecular Medicine USJ

The delta variant in Sri Lanka assigned a new sub-lineage (AY.28)